Leerink upgraded Amgen to Outperform from Market Perform with a price target of $318, up from $267. The analyst notes that the upgrade is both a multiple-expansion and earnings-upside call. Leerink expects the P/E multiple to expand due to accelerating pipeline newsflow – including in oncology, obesity, and cardiovascular disease – and also expects upward pressure on both near- and long-term EPS due to accretion from the acquisition of Horizon Therapeutics that closed on October 6, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN:
- Neumora Therapeutics appoints Lenz as EVP, Head of Research, Development
- GCOW: An ETF for Dividend and Free Cash Flow Lovers
- AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
- Amgen completes acquisition of Horizon Therapeutics
- Negative Amgen AdCom a positive for Mirati, says Jefferies
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue